
|Articles|March 15, 2004
Anti-VEGF drug expands options in treating AMD
Las Vegas-The investigational drug pegaptanib sodium (Macugen, Eyetech Pharmaceuticals) has been shown to stabilize and improve vision and showed effectiveness against all three subtypes of lesions involved in wet age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5